Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

Jun Araki; Isamu Okamoto; Ryuichiro Suto; Yasuko Ichikawa; Ji Ichiro Sasaki

doi:10.1016/j.lungcan.2004.10.012

Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

Jun Araki, Isamu Okamoto, Ryuichiro Suto, Yasuko Ichikawa, Ji Ichiro Sasaki

内科学

研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

41 被引用数 (Scopus)

抄録

Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.

本文言語	英語
ページ（範囲）	141-144
ページ数	4
ジャーナル	Lung Cancer
巻	48
号	1
DOI	https://doi.org/10.1016/j.lungcan.2004.10.012
出版ステータス	出版済み - 4月 2005

!!!All Science Journal Classification (ASJC) codes

腫瘍学
呼吸器内科
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/j.lungcan.2004.10.012

他のファイルとリンク

引用スタイル

@article{1e2ac4a328194c86ae8c27658efa3848,

title = "Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer",

abstract = "Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.",

author = "Jun Araki and Isamu Okamoto and Ryuichiro Suto and Yasuko Ichikawa and Sasaki, {Ji Ichiro}",

year = "2005",

month = apr,

doi = "10.1016/j.lungcan.2004.10.012",

language = "English",

volume = "48",

pages = "141--144",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

AU - Araki, Jun

AU - Okamoto, Isamu

AU - Suto, Ryuichiro

AU - Ichikawa, Yasuko

AU - Sasaki, Ji Ichiro

PY - 2005/4

Y1 - 2005/4

N2 - Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.

AB - Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.

UR - http://www.scopus.com/inward/record.url?scp=15044365905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044365905&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2004.10.012

DO - 10.1016/j.lungcan.2004.10.012

M3 - Article

C2 - 15777982

AN - SCOPUS:15044365905

SN - 0169-5002

VL - 48

SP - 141

EP - 144

JO - Lung Cancer

JF - Lung Cancer

IS - 1

ER -

Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

抄録

!!!All Science Journal Classification (ASJC) codes

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル